Seagen Inc (NASDAQ:SGEN)
| 175.72 Delayed Data As of 4:00pm ET |  -2.61 / -1.46%Today’s Change | 105.43 Today|||52-Week Range 192.79 | +13.66% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $36.9B |
Company Description
Seagen Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997, and is headquartered in Bothell, WA.
Contact Information
Seagen Inc. 21823 30th Drive SE Bothell Washington 98021 |
Employees
Shareholders
| Mutual fund holders | 47.96% |
| Other institutional | 42.99% |
| Individual stakeholders | 26.56% |
Top Executives
| Roger D. Dansey | Chief Executive & Medical Officer |
| Todd E. Simpson | Chief Financial Officer |
| Vaughn B. Himes | Chief Technical Officer |
| Natasha A. Hernday | Executive Vice President-Corporate Development |
| Dennis Benjamin | Senior Vice President-Translational Research |
